Clinical Report: Oculis CEO Riad Sherif, MD

Overview

The phase 2 ACUITY trial of OCS-05 in acute optic neuritis demonstrated positive safety and efficacy results, highlighting its potential as a neuroprotective treatment. Key findings include preservation of retinal thickness and improved visual function compared to steroid treatment alone.

Background

Acute optic neuritis is a demyelinating optic neuropathy often associated with multiple sclerosis, leading to significant visual impairment. Current treatments primarily involve high-dose corticosteroids, which do not address the underlying neurodegeneration. There is a pressing need for therapies that can protect neurons and preserve vision in affected patients.

Data Highlights

Key Findings

• OCS-05 achieved its primary endpoint of cardiac safety with no significant differences from placebo.
• Patients receiving OCS-05 had a lower rate of MS relapses compared to those on steroids alone (10.5% vs 35.7%).
• OCS-05 preserved ganglion cell inner plexiform layer (GCIPL) and retinal nerve fiber layer (RNFL) thickness.
• Improvements in low-contrast visual acuity were observed in patients treated with OCS-05.
• The trial results suggest potential applications for OCS-05 in other neurodegenerative diseases.

Clinical Implications

The positive results from the ACUITY trial indicate that OCS-05 may offer a new therapeutic option for patients with acute optic neuritis, addressing the unmet need for neuroprotective treatments. Clinicians should consider the potential of OCS-05 in managing acute optic neuritis and its implications for broader neuro-ophthalmic conditions.

Conclusion

The ACUITY trial results represent a significant advancement in the treatment of acute optic neuritis, with OCS-05 showing promise as a neuroprotective therapy. Further studies are warranted to explore its full potential in clinical practice.

References

1. Oculis | Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
2. Optic Neuritis Clinical Guide | Cleveland Clinic
3. Treatment of Acute Optic Neuritis: A Summary of Findings From the Optic Neuritis Treatment Trial - PMC
4. Ophthalmology Management — Oculis CEO Riad Sherif, MD Recommendations
5. Optometric Management — Create an Itemized Fee Schedule
6. Optometric Management — OD Notebook: Don’t underestimate the simplicity of practice value when selling your practice
7. Ophthalmology Management — Industry Insider
8. Ophthalmology Management — Industry Insider
9. Optometric Management — Create an Itemized Fee Schedule
10. Optometric Management — OD Notebook: Don’t underestimate the simplicity of practice value when selling your practice
11. Optic Neuritis Clinical Guide | Cleveland Clinic
12. Treatment of Acute Optic Neuritis: A Summary of Findings From the Optic Neuritis Treatment Trial - PMC
13. Oculis | Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy